Methods of inhibition of MMTV-like viruses
AssigneeGilead Sciences, Inc.
InventorsTomas Cihlar, Janet Douglas, Craig Gibbs
Life of this patent
Estimating the term…
Abstract
The active metabolites of adefovir and tenofovir (PMEApp and PMPApp) are active against the MMTV RT. They are 25-fold more potent than 3TCppp, suggesting that tenofovir and adefovir may be effective at inhibiting the MMTV-like retroviruses, which may be the etiological agents involved in PBC and breast cancer.
Claims9
A method for inhibiting the activity of MMTV-like retrovirus reverse transcriptase comprising contacting the retrovirus with an effective amount of adefovir or tenofovir.
A method for inhibiting the replication of MMTV-like retroviruses comprising contacting the retrovirus with an effective amount of adefovir or tenofovir.
A method for treating mammalian breast cancer comprising administering an effective amount of adefovir or tenofovir.
A method for treating human primary biliary cirrhosis comprising administering an effective amount of adefovir or tenofovir.
A method for treating mammalian breast cancer comprising administering from about 10 mg to about 100 mg of adefovir dipivoxil.
A method for treating human primary biliary cirrhosis comprising administering from about 10 mg to about 100 mg of adefovir dipivoxil.
A method for treating mammalian breast cancer comprising administering from about 10 mg to about 1000 mg of tenofovir disoproxil fumarate.
A method for treating human primary biliary cirrhosis comprising administering from about 10 mg to about 1000 mg of tenofovir disoproxil fumarate.
Dependencies are inferred from the claim text.